Clinical Trials / Research Studies
Neurofibromatosis Other

Solid Tumors Neurofibromatosis Other

APG-115-US-002: A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors (Open to MPNST)

  • Ages: 12 Years and older

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab. Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab. APG-115-US-002: A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unre ...More

NF110: Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110)

  • Ages: 6 Years and older

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 c ...More